{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0"}]}],"title":"Total with Absence of Residual BCC at Any Time"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5"}]}],"title":"Absence of Residual BCC Prior to Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9"}]}],"title":"Absence of Residual BCC at Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"}]}],"title":"Absence of Residual BCC After Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"In patients with locally advanced BCC, the histopathological effect of vismodegib was determined in tissue biopsies obtained at baseline (prior to study drug dosing) and at 24 weeks after the start of vismodegib treatment, if the patient was still on study without evidence of progression, or at the investigator's assessment of best clinical response (or best clinical/RECIST response), if occurring prior to 24 weeks. At any time during a patient's participation in the study, an optional tumor biopsy might have been requested to clarify the response status of the patient. Reported is the percentage of efficacy-evaluable patients with locally advanced BCC pathology that was confirmed in a baseline biopsy who had an absence of residual BCC post-baseline as assessed by an independent pathological review.","groups":[{"description":"Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.","id":"OG000","title":"Locally Advanced Basal-Cell Carcinoma"}],"paramType":"NUMBER","populationDescription":"Efficacy-evaluable population: All treated patients for whom the independent pathologist's interpretation of archival tissue or baseline biopsies was consistent with basal cell carcinoma.","reportingStatus":"POSTED","timeFrame":"At Baseline and 24 weeks, and at any optional point post-baseline through end of the study (up to the clinical cutoff date of 26 November 2010, up to 90 weeks)","title":"Percentage of Participants With Absence of Residual Basal Cell Carcinoma (BCC) in the Efficacy-Evaluable Locally Advanced BCC Cohort","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}